KR100823805B1 - 5-ｈｔ6 수용체, 5-ｈｔ2ａ 수용체 또는 둘다를 조절하기에유용한 아릴설포닐 벤조다이옥산 - Google Patents
5-ｈｔ6 수용체, 5-ｈｔ2ａ 수용체 또는 둘다를 조절하기에유용한 아릴설포닐 벤조다이옥산 Download PDFInfo
- Publication number
- KR100823805B1 KR100823805B1 KR1020067023073A KR20067023073A KR100823805B1 KR 100823805 B1 KR100823805 B1 KR 100823805B1 KR 1020067023073 A KR1020067023073 A KR 1020067023073A KR 20067023073 A KR20067023073 A KR 20067023073A KR 100823805 B1 KR100823805 B1 KR 100823805B1
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- formula
- dihydro
- benzo
- benzenesulfonyl
- Prior art date
Links
- 0 C*(C=C(C=C1Br)S([Al])(=O)=O)C=C1OC(*)(C1OC(C)(C)OC1(*)S)S Chemical compound C*(C=C(C=C1Br)S([Al])(=O)=O)C=C1OC(*)(C1OC(C)(C)OC1(*)S)S 0.000 description 10
- AGEZXYOZHKGVCM-UHFFFAOYSA-N BrCc1ccccc1 Chemical compound BrCc1ccccc1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- XJUCKEPJLQNVND-UHFFFAOYSA-N CC(C)(C=C(C=C1Br)S(C(C)=O)(=O)=O)C=C1O Chemical compound CC(C)(C=C(C=C1Br)S(C(C)=O)(=O)=O)C=C1O XJUCKEPJLQNVND-UHFFFAOYSA-N 0.000 description 1
- AUWSQNHFLDLOSH-UHFFFAOYSA-N CC(c1cc(S(c2ccccc2)(=O)=O)ccc1O)=O Chemical compound CC(c1cc(S(c2ccccc2)(=O)=O)ccc1O)=O AUWSQNHFLDLOSH-UHFFFAOYSA-N 0.000 description 1
- JSUKRBMPOXGCPR-UHFFFAOYSA-N Oc(cc1)ccc1S(c1ccccc1)(=O)=O Chemical compound Oc(cc1)ccc1S(c1ccccc1)(=O)=O JSUKRBMPOXGCPR-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
- C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
- C07D327/06—Six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56831404P | 2004-05-05 | 2004-05-05 | |
| US60/568,314 | 2004-05-05 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20070009664A KR20070009664A (ko) | 2007-01-18 |
| KR100823805B1 true KR100823805B1 (ko) | 2008-04-21 |
Family
ID=34965191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020067023073A KR100823805B1 (ko) | 2004-05-05 | 2005-04-27 | 5-ｈｔ6 수용체, 5-ｈｔ2ａ 수용체 또는 둘다를 조절하기에유용한 아릴설포닐 벤조다이옥산 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US7368567B2 (ru) |
| EP (1) | EP1748995B1 (ru) |
| JP (1) | JP2007536302A (ru) |
| KR (1) | KR100823805B1 (ru) |
| CN (1) | CN100540546C (ru) |
| AR (1) | AR048936A1 (ru) |
| AT (1) | ATE458727T1 (ru) |
| AU (1) | AU2005238179B2 (ru) |
| BR (1) | BRPI0510642A (ru) |
| CA (1) | CA2566196A1 (ru) |
| DE (1) | DE602005019562D1 (ru) |
| ES (1) | ES2338668T3 (ru) |
| HK (1) | HK1104533A1 (ru) |
| IL (1) | IL178819A0 (ru) |
| MX (1) | MXPA06012621A (ru) |
| NO (1) | NO20065510L (ru) |
| NZ (1) | NZ550441A (ru) |
| RU (1) | RU2372344C2 (ru) |
| TW (1) | TWI298636B (ru) |
| WO (1) | WO2005105776A1 (ru) |
| ZA (1) | ZA200608588B (ru) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2582273C (en) * | 2004-09-30 | 2013-10-29 | Douglas William Bonhaus | Compositions and methods for treating cognitive disorders using serotonin receptor antagonists |
| WO2006066756A1 (en) * | 2004-12-21 | 2006-06-29 | F. Hoffmann-La Roche Ag | Chroman derivatives and uses thereof in the treatment of cns disorders |
| GT200600159A (es) * | 2005-04-22 | 2007-03-14 | Derivados benzodioxano y benzodioxolano y usos de los mismos | |
| BRPI0618206A2 (pt) | 2005-11-03 | 2011-08-23 | Hoffmann La Roche | arilsulfonil cromanos como inibidores de 5-ht6, bem como composição farmacêutica, uso e processo para produção dos mesmos |
| WO2007120596A1 (en) * | 2006-04-12 | 2007-10-25 | Wyeth | DIHYDRO[1,4]DIOXINO[2,3-e]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS |
| EP2041079A1 (en) | 2006-06-20 | 2009-04-01 | F. Hoffmann-Roche AG | Arylsulfonyl naphthalene derivatives and uses thereof |
| FR2913886B1 (fr) | 2007-03-22 | 2012-03-02 | Guerbet Sa | Utilisation de nanoparticules metalliques dans le diagnostique de la maladie d'alzheimer |
| JP2011519839A (ja) * | 2008-04-29 | 2011-07-14 | エヌエスエイビー、フィリアル アヴ ノイロサーチ スウェーデン エービー、スヴェーリエ | ドーパミン神経伝達のモジュレーター |
| MX2010011498A (es) | 2008-04-29 | 2010-11-12 | Nsab Af Neurosearch Sweden Ab | Moduladores de neurotransmision de dopamina. |
| MX2010011724A (es) | 2008-04-29 | 2010-11-30 | Nsab Af Neurosearch Sweden Ab | Moduladores de neurotransmision de dopamina. |
| CN114890978B (zh) * | 2022-04-19 | 2023-07-25 | 宿迁医美科技有限公司 | 酚类化合物及其制备方法和应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003029238A1 (en) * | 2001-10-04 | 2003-04-10 | Wyeth | Chroman derivatives as 5-hydroxytryptamine-6 ligands |
| WO2003095434A1 (en) * | 2002-05-13 | 2003-11-20 | F. Hoffmann-La Roche Ag | Benzoxazine derivatives as 5-ht6 modulators and uses thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3901814A1 (de) * | 1988-07-28 | 1990-02-01 | Bayer Ag | Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga |
| TW224941B (ru) * | 1989-11-08 | 1994-06-11 | Yamanouchi Pharma Co Ltd | |
| US5506192A (en) * | 1990-06-07 | 1996-04-09 | Sandoz Ltd. | Substituted phthalides and heterocyclic phthalides |
| DE69128477T2 (de) * | 1990-07-27 | 1998-07-16 | Chugai Seiyaku K.K., Tokio/Tokyo | Benzopyranderivat |
| US5401848A (en) | 1990-11-26 | 1995-03-28 | E. R. Squibb & Sons, Inc. | Indane and quinoline derivatives |
| US5817693A (en) * | 1991-11-05 | 1998-10-06 | Cousins; Russell Donovan | Endothelin receptor antagonists |
| ZA93436B (en) * | 1992-01-24 | 1993-08-25 | Chugai Pharmaceutical Co Ltd | Benzopyran derivatives |
| ES2145129T3 (es) * | 1992-08-17 | 2000-07-01 | Chugai Pharmaceutical Co Ltd | Derivados de benzopirano y benzoxazina. |
| US5374643A (en) | 1992-09-11 | 1994-12-20 | E. R. Squibb & Sons, Inc. | Aryl urea (thiourea) and cyanoguanidine derivatives |
| GB9309716D0 (en) * | 1993-05-12 | 1993-06-23 | Zeneca Ltd | Heterocyclic derivatives |
| US5739135A (en) * | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
| US6150402A (en) * | 1994-08-15 | 2000-11-21 | Loma Linda University Medical Center | Natriuretic compounds |
| US5869478A (en) | 1995-06-07 | 1999-02-09 | Bristol-Myers Squibb Company | Sulfonamido substituted benzopyran derivatives |
| CZ418597A3 (cs) | 1995-06-30 | 1998-06-17 | Pharmacia & Upjohn Company | 1,6-disubstituované izochromany pro léčbu bolestí hlavy při migréně |
| US5663194A (en) * | 1995-07-25 | 1997-09-02 | Mewshaw; Richard E. | Chroman-2-ylmethylamino derivatives |
| US5935958A (en) * | 1996-07-01 | 1999-08-10 | Schering Corporation | Muscarinic antagonists |
| EP1019035A4 (en) * | 1996-08-21 | 2001-10-17 | Smithkline Beecham Corp | IL-8 RECEPTOR ANTAGONISTS |
| US6559144B2 (en) * | 1997-02-13 | 2003-05-06 | Merck Patent Gesellschaft Mit | Bicyclic amino acids |
| ATE390404T1 (de) * | 1997-02-27 | 2008-04-15 | Takeda Pharmaceutical | Aminderivate, ihre herstellung und verwendung als inhibitoren der produktion von amyloid-beta |
| TWI242011B (en) * | 1997-03-31 | 2005-10-21 | Eisai Co Ltd | 1,4-substituted cyclic amine derivatives |
| FR2778662B1 (fr) * | 1998-05-12 | 2000-06-16 | Adir | Nouveaux composes cycliques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| KR100660788B1 (ko) * | 1998-12-04 | 2007-02-28 | 다케다 야쿠힌 고교 가부시키가이샤 | 벤조푸란 유도체, 그 제조법 및 용도 |
| CA2404736C (en) * | 2000-04-03 | 2011-12-06 | Takeda Chemical Industries, Ltd. | Process for producing amine derivatives |
| AR035858A1 (es) * | 2001-04-23 | 2004-07-21 | Bayer Corp | Derivados de cromano 2,6-sustituidos,composiciones farmaceuticas,uso de dichos derivados para la manufactura de medicamentos utiles como agonistas adrenorreceptores beta-3 |
| WO2003029239A1 (en) * | 2001-10-04 | 2003-04-10 | Wyeth | Chroman and benzofuran derivatives as 5-hydroxytryptamine-6 ligands |
| JP4754821B2 (ja) * | 2002-06-20 | 2011-08-24 | プロキシマゲン・リミテッド | 肥満症、ｉｉ型糖尿病およびｃｎｓ障害の治療に有用な新規化合物 |
| WO2005037223A2 (en) * | 2003-10-15 | 2005-04-28 | Brigham And Women's Hospital, Inc. | Methods and compositions for immunomodulation |
| US20070208166A1 (en) | 2003-10-24 | 2007-09-06 | Exelixis, Inc. | Tao Kinase Modulators And Method Of Use |
-
2005
- 2005-04-27 BR BRPI0510642-7A patent/BRPI0510642A/pt not_active IP Right Cessation
- 2005-04-27 MX MXPA06012621A patent/MXPA06012621A/es active IP Right Grant
- 2005-04-27 ES ES05734404T patent/ES2338668T3/es active Active
- 2005-04-27 EP EP05734404A patent/EP1748995B1/en active Active
- 2005-04-27 JP JP2007511952A patent/JP2007536302A/ja not_active Ceased
- 2005-04-27 CA CA002566196A patent/CA2566196A1/en not_active Abandoned
- 2005-04-27 DE DE602005019562T patent/DE602005019562D1/de active Active
- 2005-04-27 CN CNB2005800143682A patent/CN100540546C/zh not_active Expired - Fee Related
- 2005-04-27 WO PCT/EP2005/004479 patent/WO2005105776A1/en active Application Filing
- 2005-04-27 KR KR1020067023073A patent/KR100823805B1/ko not_active IP Right Cessation
- 2005-04-27 AU AU2005238179A patent/AU2005238179B2/en not_active Ceased
- 2005-04-27 NZ NZ550441A patent/NZ550441A/en unknown
- 2005-04-27 RU RU2006138180/04A patent/RU2372344C2/ru not_active IP Right Cessation
- 2005-04-27 AT AT05734404T patent/ATE458727T1/de not_active IP Right Cessation
- 2005-05-02 AR ARP050101740A patent/AR048936A1/es unknown
- 2005-05-03 TW TW094114308A patent/TWI298636B/zh not_active IP Right Cessation
- 2005-05-04 US US11/121,873 patent/US7368567B2/en not_active Expired - Fee Related
-
2006
- 2006-10-13 ZA ZA200608588A patent/ZA200608588B/en unknown
- 2006-10-23 IL IL178819A patent/IL178819A0/en unknown
- 2006-11-29 NO NO20065510A patent/NO20065510L/no not_active Application Discontinuation
-
2007
- 2007-09-05 HK HK07109656.9A patent/HK1104533A1/xx not_active IP Right Cessation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003029238A1 (en) * | 2001-10-04 | 2003-04-10 | Wyeth | Chroman derivatives as 5-hydroxytryptamine-6 ligands |
| WO2003095434A1 (en) * | 2002-05-13 | 2003-11-20 | F. Hoffmann-La Roche Ag | Benzoxazine derivatives as 5-ht6 modulators and uses thereof |
Non-Patent Citations (2)
| Title |
|---|
| WO 03/029238 A1. |
| WO 03/095434 A1. |
Also Published As
| Publication number | Publication date |
|---|---|
| US20050250943A1 (en) | 2005-11-10 |
| TWI298636B (en) | 2008-07-11 |
| EP1748995B1 (en) | 2010-02-24 |
| ATE458727T1 (de) | 2010-03-15 |
| MXPA06012621A (es) | 2006-12-15 |
| IL178819A0 (en) | 2007-03-08 |
| DE602005019562D1 (de) | 2010-04-08 |
| AU2005238179B2 (en) | 2010-08-26 |
| US7368567B2 (en) | 2008-05-06 |
| WO2005105776A8 (en) | 2007-01-11 |
| NZ550441A (en) | 2009-07-31 |
| TW200605894A (en) | 2006-02-16 |
| AR048936A1 (es) | 2006-06-14 |
| CN1960983A (zh) | 2007-05-09 |
| CA2566196A1 (en) | 2005-11-10 |
| WO2005105776A1 (en) | 2005-11-10 |
| HK1104533A1 (en) | 2008-01-18 |
| RU2006138180A (ru) | 2008-06-10 |
| BRPI0510642A (pt) | 2007-11-20 |
| ES2338668T3 (es) | 2010-05-11 |
| RU2372344C2 (ru) | 2009-11-10 |
| JP2007536302A (ja) | 2007-12-13 |
| EP1748995A1 (en) | 2007-02-07 |
| KR20070009664A (ko) | 2007-01-18 |
| ZA200608588B (en) | 2008-06-25 |
| NO20065510L (no) | 2007-01-12 |
| AU2005238179A1 (en) | 2005-11-10 |
| CN100540546C (zh) | 2009-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100823805B1 (ko) | 5-ｈｔ6 수용체, 5-ｈｔ2ａ 수용체 또는 둘다를 조절하기에유용한 아릴설포닐 벤조다이옥산 | |
| US7378415B2 (en) | Benzoxazine and quinoxaline derivatives and uses thereof | |
| KR100843053B1 (ko) | 중추 신경계 질환의 치료를 위한 5-하이드록시트립트아민수용체(5-ｈｔ)의 조절제로서1-벤질-5-피페라진-1-일-3,4-다이하이드로-1ｈ-퀴나졸린-2-온 유도체 및 각각의1ｈ-벤조(1,2,6)티아다이아진-2,2-다이옥사이드 및1,4-다이하이드로-벤조(ｄ)(1,3)옥사진-2-온 유도체 | |
| JP2008524275A (ja) | クロマン誘導体及び５−ｈｔレセプターリガンドとしてのそれらの使用 | |
| KR100691090B1 (ko) | 퀴놀리논/벤즈옥사지논 유도체 및 이들의 용도 | |
| KR100827915B1 (ko) | 벤즈옥사진 유도체 및 그의 용도 | |
| US7307089B2 (en) | Aryloxy quinolines and uses thereof | |
| AU2005291541B2 (en) | Benzoxazine and quinoxaline derivatives and uses | |
| KR100965190B1 (ko) | 크로만 유도체 및 중추 신경계 장애의 치료에서 그의 용도 | |
| KR100984897B1 (ko) | 5-ｈｔ6 억제제로서 아릴설포닐 크로만 | |
| Berger et al. | Arylsulfonyl chromans as 5-HT 6 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| LAPS | Lapse due to unpaid annual fee |